ADIPEX pytanie do ekspertów

Witam nie wiem czy wstrzeliłem sie z działem zatem temat mozna dowolnie przesunąć . Do meritum . Chodzi mi o srodek który hamuje łaknienie . Kto z was tego uzywal jakie skutki uboczne . Miejsce i rok produkcji leku kiedy go u nas wycofali ? Itd itp . Bedę wdzięczny za wszelkie info .

O ile wiem ten lek bo jest to lek jest dosttępny w czechach tylko i nazywa sie dokładnie ADIPEX-RETARD. ja jeszcze pamietam ze nie moga brac tego osoby które maja miazdzyce, nadciśnienie i ze podczas kuracji nie wolno pic alkocholu.

Pozatym dam ci linka , gdzie grasik rewelacyjnie to opisała wszystko
https://www.sfd.pl/temat65900/ 

mam nadzieje, ze ponizsze info tobie wystarczy...
z tego, co wiem, adipex nie jest dostepny w polsce, gdyz soobstancja czynna leku nie zostala tu zarejestrowana; poza tym fentermina, na ktoorej oparty jest adipex, znajdooje sie na liscie zakazanych srodkoow farmakologicznych /mkol/


ADIPEX-P ORAL
Patient Handout

APPETITE SUPPRESSANTS - ORAL
The following information is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. Consult your healthcare professional before using this drug.

Uses
This medication is used in combination with a diet plan to help you reduce weight.

How to Take this Medication
This medication is best taken on an empty stomach one hour before a meal. Sustained-release or long acting products must be swallowed whole. Crushing or chewing them will destroy the long action and may cause increased side effects. Because this medication may cause sleeplessness, avoid taking a dose late in the day. Take this medication as prescribed. Do not take it more often or longer than directed. It is usually taken for 8 to 12 weeks. Use in combination with other appetite suppressant medicine is generally not recommended. Consult your doctor before such use.

Side Effects
Blurred vision, dizziness, dry mouth, sleeplessness, irritability, stomach upset or constipation may occur the first few days as your body adjusts to the medication. If these effects persist or become bothersome, inform your doctor. Notify your doctor if you experience: chest pain, nervousness, pounding heart, difficulty urinating, mood changes, breathing difficulties, swelling. If this medication makes you dizzy or lightheaded, avoid driving or engaging in activities requiring alertness. If you notice other effects not listed above, contact your doctor or pharmacist.

Precautions
Tell your doctor your complete medical history, especially if you have: high blood pressure, an over-active thyroid, glaucoma, diabetes, emotional problems. This medication can be habit forming and must be used with caution. Alcohol can increase unwanted side effects of dizziness. Limit alcohol use. This drug is not recommended for use in children. Consult your doctor or pharmacist for further information. This medication should be used only when clearly needed during pregnancy. Discuss the risk and benefits with your doctor. This drug may be excreted into breast milk. You may have to stop nursing or stop using this drug. Consult your doctor before breast-feeding.

Interactions
Inform your doctor about all the medicines you use, (prescription and nonprescription) especially if you take: high blood pressure medicine, MAO inhibitors (e.g., furazolidone, linezolid, phenelzine, selegiline, tranylcypromine), any other weight loss medicine. Avoid "stimulant" drugs that may increase your heart rate such as decongestants or caffeine. Decongestants are commonly found in over-the-counter cough-and-cold medicines. Do not start or stop any medicine without doctor or pharmacist approval.

Overdose
If overdose is suspected, contact your local poison control center at 1-800-222-1222 (USA) or emergency room immediately. Symptoms of overdose may include restlessness, fever, fast breathing, dizziness, confusion, hallucinations, panic or paranoid, drowsiness, convulsions, unconsciousness, unusually fast or slow heart beat, headache, nausea/vomiting, diarrhea, stomach pain, pale or flushing, chest pain, sweating, muscle weakness, agitation, large pupils, or delusions.

Notes
Appetite suppressants are not a substitute for proper diet. For maximum effects, this must be used in conjunction with a diet and exercise program. Do not share this medication with others.

Administration
Phentermine is administered orally in the form of the hydrochloride salt or the resin complex.

Dosage
The usual adult dosage of phentermine hydrochloride is 8 mg 3 times daily, given 30 minutes before meals. Alternatively, 15 or 30 mg of phentermine as the resin complex, or 15–37.5 mg of phentermine hydrochloride, may be given as a single daily dose in the morning.

Missed Dose
If you miss a dose, do not double the next dose. Instead, skip the missed dose and resume your usual dosing schedule.

Storage
Store at room temperature away from sunlight and moisture. Do not store in the bathroom.


Uses from AHFS DI™
Phentermine is used as an adjunct to exercise, behavioral modification, and caloric restriction in the short-term management (a few weeks) of exogenous obesity. Phentermine therapy is indicated for patients with no underlying risk factor but a pretreatment body mass index (BMI) of 30 kg/m2 or greater and those with an underlying risk factor (e.g., hypertension, diabetes mellitus, hyperlipidemia) and a pretreatment BMI of 27 kg/m2 or greater. Phentermine is indicated only for monotherapy in the management of exogenous obesity; the drug should not be used in combination with selective serotonin-reuptake inhibitor antidepressants (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) or monoamine oxidase (MAO) inhibitors. To help bring about and maintain loss of weight, the patient must be taught to curtail overeating and to consume a suitable diet. Phentermine also has been used for longer periods combined with fenfluramine (no longer commercially available in the US) in selected patients for the management of this condition. Such combined long-term therapy had been used widely in the 1990s in the management of exogenous obesity. However, because of accumulated data on adverse effects associated with the drugs, fenfluramine hydrochloride (Pondimin®) and its dextrorotatory isomer dexfenfluramine hydrochloride (Redux®) were withdrawn from the US market in 1997. (See Cautions and also see Cautions, in the Amphetamines General Statement 28:20.)



Drug Interactions


Contraindicated Drug Combination:
This drug combination is clearly contraindicated in all cases and should not be dispensed or administered to the same patient.
• SYMPATHOMIMETICS/MAOIS; FURAZOLIDONE
Increased effect of the former drug

Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
• PHENTERMINE/SSRI'S
Adverse reaction with both drugs
• SELECTED INHALATION ANESTHETIC AGENTS/SYMPATHOMIMETICS
Adverse reaction of the former drug
• SYMPATHOMIMETICS/TRICYCLIC COMPOUNDS
Mixed effects of the former drug


Drug Interactions from AHFS DI™
Insulin requirements in patients with diabetes mellitus may be decreased in association with the use of phentermine and the concomitant dietary regimen and weight loss; therefore, phentermine should be used with caution in patients with diabetes mellitus.Like amphetamines, phentermine may decrease the hypotensive effect of guanethidine.


Precautions

Drug Disease Contraindications

Most Significant
If you have any of these conditions and are taking this product, contact your doctor immediately.

• Arteriosclerosis Obliterans
• Cardiovascular Disease
• Pulmonary Hypertension
• Hypertension
• Glaucoma
• Feeling Agitated
• Drug Abuse
• Alcoholism
• Hyperthyroidism
Possibly Significant

If you have any of these conditions and are taking this product, you may want to talk to your doctor

• Psychotic Disorder
• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus
Pediatric Precautions
NO STUDIES HAVE BEEN DONE BUT WARNINGS EXIST

• Precaution active between 1 days and 4380
Lactation Precautions
PRECAUTION

• NO DATA AVAILABLE.
• EFFECT ON THE INFANT IS UNKNOWN
Pregnancy Precaurions
ANIMAL STUDIES HAVE SHOWN ADVERSE EFFECT ON FETUS BUT NO WELL-CONTROLLED STUDIES IN HUMANS: POTENTIAL BENEFITS MAY WARRANT USE IN PREGNANT WOMEN DESPITE POTENTIAL RISKS; OR NO ANIMAL REPRODUCTION STUDIES AND NO ADEQUATE AND WELL-CONTROLLED STUDIES IN HUMANS.


Geriatric Precautions
CONTRAINDICATION

• MAY PRECIPITATE HYPERTENSION,ANGINA & MI IN ELDERLY
•; Cardiovascular Effects
•; Neurological Effects


Precautions and Contraindications
Patients should be warned that phentermine may impair their ability to perform activities requiring mental alertness or physical coordination (e.g., operating machinery, driving a motor vehicle). Phentermine should be used with caution in patients with mild hypertension, and blood pressure should be closely monitored.Pulmonary hypertension has been reported in patients receiving phentermine in combination with dexfenfluramine (no longer commercially available in the US), fenfluramine (no longer commercially available in the US), and in those with a history of receiving at least one other anorexigenic agent; however, the possibility of an association between pulmonary hypertension and the use of phentermine as monotherapy cannot be ruled out. Primary pulmonary hypertension is a rare, frequently fatal pulmonary disease. The initial symptom of pulmonary hypertension generally is dyspnea. Other initial manifestations include angina pectoris, syncope, or edema of the lower extremities. Phentermine should be discontinued in any patient who develops new, unexplained symptoms of dyspnea, angina, syncope, or edema of the lower extremities. Such patients should be evaluated for the possible presence of pulmonary hypertension. In addition, patients receiving phentermine should be advised to report immediately any deterioration in exercise tolerance.Phentermine should not be used in combination with selective serotonin-reuptake inhibitor antidepressants (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) or MAO inhibitors, since severe adverse reactions may occur. In addition, one manufacturer of phendimetrazine tartrate (Plegine®) states that phendimetrazine should not be used in combination with other anorexigenic agents (e.g., phentermine) since valvulopathy and primary pulmonary hypertension have been reported in patients receiving phendimetrazine who had received at least one other anorexigenic agent.Habituation or addiction has been reported with similar drugs and the possibility of its occurrence should be considered with phentermine.Phentermine is contraindicated in patients with advanced arteriosclerosis, hyperthyroidism, moderate to severe hypertension, symptomatic cardiovascular disease, agitated states, a history of drug abuse, glaucoma, or known hypersensitivity or idiosyncrasy to sympathomimetic amines. In addition, the drug is contraindicated during or within 14 days of administration of monoamine oxidase inhibitors.

Pediatric Precautions
Use of phentermine in children younger than 16 years of age is not recommended.

Pregnancy
Safe use of phentermine during pregnancy has not been established. During pregnancy it is questionable whether potential benefits from anorexigenic agents outweigh potential risks and this condition should probably be considered a contraindication to their use, especially during the first trimester.


Adverse Effects List

More Frequent
FALSE SENSE OF WELL-BEING
INCREASED BLOOD PRESSURE severe
NERVOUSNESS
TROUBLE SLEEPING

Less Frequent
ALLERGIC DERMATITIS severe
ALLERGIC REACTION severe
BLURRED VISION
CHANGES IN LIBIDO
CONSTIPATION
DIARRHEA
DIZZINESS
DROWSINESS
DRY MOUTH
DYSURIA
HEADACHE
HIVES severe
IRREGULAR HEARTRATE
SKIN RASH severe
STOMACH PAIN/CRAMPS

Rare or Very Rare
CONFUSION severe
DEPRESSION severe
IMPOTENCE
INCREASED SWEATING
NAUSEA
PSYCHOSIS severe
UNPLEASANT TASTE
URINARY FREQUENCY
VOMITING

Dokladniej został zarejstrowany w polsce ale jak zaczeły wybuchać skandale w 90 latach został wycofany we wszystkich postaciach . Mnie interesuje kto to brał z forumowiczów . Jakie efekty i kto później miał problemy z sercem . A tak dla ciekawostki : http://www.ptk.waw.pl/dyskusja.html 

Czytałeś tego linka co ci dałem? tam przeciesz masz to

Czytałem.
Cyt. tam przecież masz to . To znaczy czyli co ? Nie widziałem tam odpowiedzi na pytanie które zadawałem . Moze coś przeoczyłem napisz mi w której cześci tamtego tematu jest to "To".

bez sensu takie cos zapodawac...
zainteresuj sie lepiej synefryną

palisz papierosy ?

wrzuć cos na ten temat chetnie poczytam .

Synephrine is a biogenic amine derived from the Citrus aurantium fruit, which is used for a variety of reasons in Traditional Chinese Medicine. It can be used both to aid in fat loss and as an appetite suppressant and animal models indicate that it may aid in alleviating depression.

The mechanism of action of synephrine is relatively unique among weight loss aids. Synephrine is an agonist of the alpha(1) adrenoreceptor [1-2], which is involved in many physiological processes. This adrenoreceptor plays a variety of roles in adipose tissue, such as modulating intracellular Ca2+ and protein kinase C levels and glycogenolysis and lactate production [3]. Correspondingly, alpha(1) agonists increase lipolysis in a variety of experimental paradigms [3-6], including an in vivo increase in lipolysis in human white adipose tissue [4]. This effect is potentiated by beta receptor stimulation, adenosine antagonism, and elevated cAMP levels [5-7], so ephedrine, caffeine, and forskolin may all be synergistic with synephrine. The appetite suppression caused by some agents is also known to be due to alpha(1) agonism [8], so synephrine can also be expected to aid in a fat loss plan in this regard.

The dosage of synephrine typically used is 10-20 mg daily, although some use as much as 50 mg daily. It is recommended to start with a low dose and work up, and exercise caution when combining synephrine with stimulants. Synephrine should not be taken if one is taking an MAO inhibitor or blood pressure medication.

If you have any questions or comments regarding this article, please email [email protected].

1. Song DK, Suh HW, Jung JS, Wie MB, Son KH, Kim YH. Antidepressant-like effects of p-synephrine in mouse models of immobility tests. Neurosci Lett. 1996 Aug 23;214(2-3):107-10. [abstract]

2. Brown CM, McGrath JC, Midgley JM, Muir AG, O'Brien JW, Thonoor CM, Williams CM, Wilson VG. Activities of octopamine and synephrine stereoisomers on alpha-adrenoceptors. Br J Pharmacol. 1988 Feb;93(2):417-29. [abstract]

3. Flechtner-Mors M, Jenkinson CP, Alt A, Adler G, Ditschuneit HH. In vivo alpha(1)-adrenergic lipolytic activity in subcutaneous adipose tissue of obese subjects. J Pharmacol Exp Ther. 2002 Apr;301(1):229-33. [abstract]

4. Boschmann M, Krupp G, Luft FC, Klaus S, Jordan J. In vivo response to alpha(1)-adrenoreceptor stimulation in human white adipose tissue. Obes Res. 2002 Jun;10(6):555-8. [abstract]

5. Zhao J, Cannon B, Nedergaard J. alpha1-Adrenergic stimulation potentiates the thermogenic action of beta3-adrenoreceptor-generated cAMP in brown fat cells. J Biol Chem. 1997 Dec 26;272(52):32847-56. [Abstract]

6. Schimmel RJ, Elliott ME, Dehmel VC. Interactions between adenosine and alpha 1-adrenergic agonists in regulation of respiration in hamster brown adipocytes. Mol Pharmacol. 1987 Jul;32(1):26-33. [abstract]

7. Raasmaja A, Larsen PR. Alpha 1- and beta-adrenergic agents cause synergistic stimulation of the iodothyronine deiodinase in rat brown adipocytes. Endocrinology. 1989 Nov;125(5):2502-9. [abstract]

8. Cheng JT, Kuo DY. Both alpha1-adrenergic and D(1)-dopaminergic neurotransmissions are involved in phenylpropanolamine-mediated feeding suppression in mice. Neurosci Lett. 2003 Aug 21;347(2):136-8. [abstract]

chyba nie jestem zainteresowany